Annual report pursuant to Section 13 and 15(d)

Collaboration and Research Arrangements - Collaboration Agreement (Details)

v3.10.0.1
Collaboration and Research Arrangements - Collaboration Agreement (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Jan. 08, 2018
Jan. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Deferred revenue recognized     $ 2,100  
Deferred revenue        
Deferred revenue     10,202 $ 0
Deferred revenue, current     1,900  
Deferred revenue, long-term     $ 8,276  
Incyte | Collaboration Agreement        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Up-front consideration   $ 10,000    
Up-front consideration, cash   2,500    
Up-front consideration, pre-paid research funding   $ 7,500    
Maximum target selection milestone payments and option exercise fees the Company is eligible to receive $ 54,000      
Maximum development and regulatory milestone payments the Company is eligible to receive for each of the validated targets 50,000      
Maximum commercial milestone payments the Company is eligible to receive for each of the validated targets if products arising from collaboration are approved $ 65,000      
Period of written notice to terminate the agreement by Incyte 60 days      
Period of written notice to terminate the agreement by the Company in the event the counterparty or one of its affiliates or sublicenses challenges the validity or enforceability of certain patent rights controlled by the Company 30 days      
Period of written notice to terminate the agreement by either of the parties in the event of an uncured material breach of the collaboration agreement by the other party 30 days      
Total transaction price $ 12,300      
Upfront non-refundable and non-creditable payment 2,500      
Prepaid research amount 7,500      
Premium paid on equity investment $ 2,300